WO2010020619A3 - Susceptibility to dasatinib - Google Patents

Susceptibility to dasatinib Download PDF

Info

Publication number
WO2010020619A3
WO2010020619A3 PCT/EP2009/060641 EP2009060641W WO2010020619A3 WO 2010020619 A3 WO2010020619 A3 WO 2010020619A3 EP 2009060641 W EP2009060641 W EP 2009060641W WO 2010020619 A3 WO2010020619 A3 WO 2010020619A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cell
treatment
dasatinib
transgenic
Prior art date
Application number
PCT/EP2009/060641
Other languages
French (fr)
Other versions
WO2010020619A2 (en
Inventor
Roman Thomas
Martin Sos
Jonathan Weiss
Thomas Zander
Peter Frommolt
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Universität Zu Köln
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V., Universität Zu Köln filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Publication of WO2010020619A2 publication Critical patent/WO2010020619A2/en
Publication of WO2010020619A3 publication Critical patent/WO2010020619A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/157—A reaction step characterised by the number of molecules incorporated or released
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to dasatinib. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with dasatinib is described herein. Furthermore, an in vitro method for the identification of a responder for or a patient sensitive to an dasatinib is disclosed and uses of an oligo- or polynucleotide capable of detecting (an) the amplification status of at least one gene selected from the group consisting of SRC, EPHA3, FRK, EPHA5, EPHA8, YES, ABL2, LCK and BLK gene are provided. The present invention also relates to a method of diagnosing non-small cell lung cancer and a method of monitoring the efficacy of a treatment of said cancer. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular a non-small cell lung cancer. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one amplified marker gene as defined herein for screening and/or validation of a medicament for the treatment of said cancer is described and a kit useful for carrying out the methods described herein is provided.
PCT/EP2009/060641 2008-08-18 2009-08-17 Susceptibility to dasatinib WO2010020619A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08014655.8 2008-08-18
EP08014655 2008-08-18

Publications (2)

Publication Number Publication Date
WO2010020619A2 WO2010020619A2 (en) 2010-02-25
WO2010020619A3 true WO2010020619A3 (en) 2010-06-24

Family

ID=41284106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/060641 WO2010020619A2 (en) 2008-08-18 2009-08-17 Susceptibility to dasatinib

Country Status (1)

Country Link
WO (1) WO2010020619A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2562265A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
EP2561867A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
JP2013116051A (en) * 2011-12-01 2013-06-13 Sysmex Corp Method for determining sensitivity of tumor cell to dasatinib and use thereof
WO2014043628A1 (en) * 2012-09-14 2014-03-20 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
WO2021043953A1 (en) * 2019-09-05 2021-03-11 Pamgene Bv Kinase activity signatures for predicting the response of non-small-cell lung carcinoma patients to a pd-1 or pd-l1 immune checkpoint inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005035A2 (en) * 2004-06-30 2006-01-12 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine pathways in lung cancer cells
US20070161019A1 (en) * 2005-11-04 2007-07-12 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
US20070254295A1 (en) * 2006-03-17 2007-11-01 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005035A2 (en) * 2004-06-30 2006-01-12 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine pathways in lung cancer cells
US20070161019A1 (en) * 2005-11-04 2007-07-12 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
US20070254295A1 (en) * 2006-03-17 2007-11-01 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AMACHIKA TOMOKO ET AL: "Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers.", LUNG CANCER (AMSTERDAM, NETHERLANDS) JUN 2007, vol. 56, no. 3, June 2007 (2007-06-01), pages 337 - 340, XP002575640, ISSN: 0169-5002 *
BLUME-JENSEN P ET AL: "ONCOGENIC KINASE SIGNALLING", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 411, no. 6835, 17 May 2001 (2001-05-17), pages 355 - 365, XP001156920, ISSN: 0028-0836 *
DU JINYAN ET AL: "Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy", NATURE BIOTECHNOLOGY, vol. 27, no. 1, January 2009 (2009-01-01), pages 77 - 83, XP002558123, ISSN: 1087-0156 *
GIACCONE G ET AL: "Src as a potential therapeutic target in non-small-cell lung cancer.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUL 2008, vol. 19, no. 7, July 2008 (2008-07-01), pages 1219 - 1223, XP002558117, ISSN: 1569-8041 *
HAFNER CHRISTIAN ET AL: "Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 50, no. 3, 1 March 2004 (2004-03-01), pages 490 - 499, XP002498092, ISSN: 0009-9147 *
HUANG FEI ET AL: "Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection", CANCER RESEARCH, vol. 67, no. 5, March 2007 (2007-03-01), pages 2226 - 2238, XP002558115, ISSN: 0008-5472 *
QUINTAS-CARDAMA A ET AL: "Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies", LEUKEMIA (BASINGSTOKE), vol. 22, no. 6, June 2008 (2008-06-01), pages 1117 - 1124, XP002558118, ISSN: 0887-6924 *
SONG LANXI ET AL: "Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival", CANCER RESEARCH, vol. 66, no. 11, June 2006 (2006-06-01), pages 5542 - 5548, XP002558116, ISSN: 0008-5472 *
SOS ET AL: "Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions", THE JOURNAL OF CLINICAL INVESTIGATION,, vol. 119, no. 6, 18 May 2009 (2009-05-18), pages 1727 - 1740, XP002555300 *
SURAWSKA H ET AL: "The role of ephrins and Eph receptors in cancer", CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 15, no. 6, 1 December 2004 (2004-12-01), pages 419 - 433, XP004652022, ISSN: 1359-6101 *
WICKS I P ET AL: "MOLECULAR CLONING OF HEK, THE GENE ENCODING A RECEPTOR TYROSINE KINASE EXPRESSED BY HUMAN LYMPHOID TUMOR CELL LINES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. (PNAS), NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 89, 1 March 1992 (1992-03-01), pages 1611 - 1615, XP000615502, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2010020619A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
NZ564923A (en) Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
MX2010010465A (en) A method for detecting igf1r/chr 15 circulating tumor cells using fish.
PL1712639T3 (en) Method for the diagnosis of cancer by detecting circulating DNA and RNA
WO2009047756A3 (en) Methods and kits for diagnosing lung cancer
WO2010020619A3 (en) Susceptibility to dasatinib
ATE486285T1 (en) METHOD FOR EARLY DETECTION OF CANCER
MX2009012722A (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
WO2006073682A3 (en) Diagnostic test
WO2008079269A3 (en) Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2009007855A3 (en) Reversible sirna-based silencing of mutant and endogenous wild-type huntingtin gene and its application for the treatment of huntington's disease
EP2612928A3 (en) Markers for prenatal diagnosis and monitoring
WO2007102891A3 (en) Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
WO2010019550A3 (en) Method of identifying disease risk factors
WO2008108803A3 (en) Immune cell biosensors and methods of using same
MX2012001000A (en) Method and kit for detecting microorganisms.
NZ593628A (en) Genetic variants useful for risk assessment of thyroid cancer using rs944289
MX2012002411A (en) Assay methods for mdv-1.
WO2008084319A3 (en) Novel nucleic acid
WO2007057746A3 (en) Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
WO2008019006A3 (en) Serum dna methylation screening for cancer
EP1988178A3 (en) Nucleotide primer set and nucleotide probe for detecting genotype of serum amyloid A1(SAA1)
AU2006228990A8 (en) A method of diagnosis and treatment and agents useful for same
EP1760160A3 (en) Methods and kits for detecting genetically modified organisms (GMO)
WO2012064978A3 (en) Compositions, methods, and kits for detecting and identifying mycobacteria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09781926

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09781926

Country of ref document: EP

Kind code of ref document: A2